Risk Factors
Transparent risk disclosure builds investor confidence. Every risk below is specific to Mere, its business model, and its Pre-Seed SAFE offering at a $9M post-money valuation cap. Each includes severity, likelihood, and a concrete mitigation strategy.
Identified Risks
Eight material risks organized by severity and likelihood. Expand each for the full assessment and mitigation strategy.
Mitigation Framework
Mere does not rely on hope to manage risk. Four structural decisions, made before fundraising, reduce exposure across every category above.
Owned Distribution
Owned clinics provide a controlled launch channel. No dependence on paid acquisition or marketplace algorithms. Practitioners are relationships, not ad impressions.
Exclusive Manufacturing
Okchundang is an equity investor, not a contract manufacturer. Patented extraction technology with 15 years of R&D creates a manufacturing moat that cannot be replicated.
Metric-Gated Deployment
Ring launch, DTC expansion, and geographic scaling all require specific metric thresholds. No milestone is calendar-gated. This prevents premature scaling.
B2B2C Before DTC
Launching through practitioners validates retention before spending on consumer acquisition. If churn is higher than modeled, the company discovers it at low cost, not after committing to paid channels.
Forward-Looking Statements
This platform contains forward-looking statements within the meaning of the federal securities laws. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any results expressed or implied by such forward-looking statements.
Forward-looking statements include, but are not limited to: projections of subscriber growth (including the target of 5,316 active subscribers by month 12), revenue estimates (including $410,000 normalized MRR), practitioner activation targets (400 activated practitioners by Q1 2027), unit economics assumptions (22.5% trial-to-paid conversion, 5% monthly churn, $21.65 to $23.35 contribution margin), product development timelines (Mere Pulse ring, NORA AI replication study), and statements regarding market opportunity and competitive positioning.
These forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation and are subject to the risks and uncertainties described above. Mere undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this platform.
See the full Regulatory Disclosures page for additional important information.